Gemfibrozil
Brand names: Gemfibrozil, Lopid
At a glance
- Medicare prescriptions, 2024
- 423,387
- Medicare drug cost
- $7.4M
- Average cost per prescription
- $17.48
- Clinicians who prescribed it
- 19,769
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied.
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 36.4%
- Internal Medicine 28.9%
- Nurse Practitioners 16.2%
- General Practice 5.9%
- Physician Assistants 4.6%
- Cardiology 2.1%
- Geriatric Medicine 1.3%
- Interventional Cardiology 0.8%
- Nephrology (Kidney) 0.6%
- Endocrinology & Diabetes 0.6%
- Hospitalist 0.3%
- Infectious Disease 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 36% from 2019 to 2024.
Biggest change by state since 2019
- South Dakota −30%
- Illinois −30%
- New Jersey −30%
- Arkansas −30%
- Puerto Rico −31%
- California (smallest change) −43%
- Oregon (smallest change) −43%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Northstar Rxllc
| Strength | Looks like | Imprint |
|---|---|---|
| 600 mg | white oval tablet, 19 mm, scored to split in 2 | N111 |
Preferred Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 600 mg | white oval tablet, 18 mm, scored to split in 2 | 1 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 600 mg | white oval tablet, 19 mm | E 82 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.